Genmab A/S (Nasdaq: GMAB, 0MGB), the Copenhagen-headquartered international biotechnology company focused on innovative antibody medicines for cancer and other serious diseases, has announced a capital increase of 164,828 ordinary shares following the exercise of employee warrants. The company states that proceeds to Genmab amount to approximately DKK 369.7 million, with shares subscribed in cash across 22 separate exercise price tranches. The capital increase represents approximately 0.2641% of Genmab's total share capital, bringing the total nominal share capital to DKK 62,570,683 following registration.

Key Points

  • Genmab A/S (Nasdaq: GMAB, 0MGB) — international biotechnology company headquartered in Copenhagen, Denmark
  • Share capital increased by 164,828 ordinary shares as a result of employee warrant exercises
  • Proceeds of approximately DKK 369.7 million; capital increase equals approximately 0.2641% of total share capital; total share capital now DKK 62,570,683
  • Investors should watch for confirmation of registration with the Danish Business Authority and subsequent Nasdaq Copenhagen listing of the new shares

Genmab's 164,828 New Shares Issued Across 22 Employee Warrant Tranches at Prices from DKK 1,362.5 to DKK 3,172

The announcement states that the 164,828 new shares were subscribed in cash across 22 distinct price tranches, ranging from DKK 1,362.5 per share at the lowest to DKK 3,172 per share at the highest. The largest single tranche comprises 34,552 shares at DKK 2,175, with other sizeable tranches including 27,772 shares at DKK 2,661 and 25,635 shares at DKK 2,070. The wide range of subscription prices reflects employee warrant grants made across multiple periods, as warrant exercise prices typically correspond to the company's share price at the time of original grant. Total proceeds of approximately DKK 369.7 million flow directly to Genmab.

New Ordinary Shares Carry Full Dividend Rights and Will List on Nasdaq Copenhagen After Danish Business Authority Registration

The announcement confirms that the new shares are ordinary shares with no special rights attached, are freely transferable, and carry full entitlement to dividends and other shareholder rights from the point of subscription. Genmab states the increase was effected without pre-emption rights for existing shareholders. The new shares are expected to be listed on Nasdaq Copenhagen following registration with the Danish Business Authority, with the capital increase described as expected to be finalised shortly. Following completion, Genmab's total share capital will consist of 62,570,683 shares of DKK 1 nominal value each, representing an equivalent number of votes.

Genmab's Antibody Medicine Pipeline and Eight Approved Products Underpin the Employee Incentive Scheme Driving This Warrant Exercise

Established in 1999, Genmab has built a portfolio of eight approved antibody medicines over more than 25 years of operation, with its science underpinning therapeutic formats including bispecific antibodies, antibody–drug conjugates, and immune-modulating antibodies. The company operates across North America, Europe, and Asia Pacific. Employee warrant programmes are a standard mechanism in biotechnology to retain specialist scientific and commercial talent; the scale of this exercise, generating approximately DKK 369.7 million in proceeds, reflects the breadth of Genmab's employee incentive arrangements. Investors may note that dilution from this tranche is limited to approximately 0.2641% of total share capital.